The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies

• Published in: Gastro hep advances Vol. 1; no. 6; pp. 1049 - 1087
• Main Authors: Tapper, Elliot B., Fleming, Charlotte, Rendon, Adriana, Fernandes, João, Johansen, Pierre, Augusto, Margarida, Nair, Sunita
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 2022; Elsevier
• Subjects: Liver Transplantation; Mortality; Progression; Risk Factors; NAS; ASCVD; STI; HR; UDCA; MetS-Z; LOXL2; SAF-A, Steatosis, Activity; α-SMA; UHC; NMEDW; DDLT; re-LT; E/e; UNOS; hs-CRP; AIH; AC; AF; Risk Factors; CVD; ACE2; MetS; MELD; UAB; FIB-4; SRTR; OPTN; Progression; Liver Transplantation; RCT; C; ELTR; F; ASH; BMI; FGF21; CC; AST; CF; WHVP; CI; ECG; NASH; TC; CS; r; VCAM-1; CV; TG; GGT; ALD; ELF; MTF; LT; ALT; AUC; HDL-C; NFS; PBO; HBV; NAFL; PIVENS; LDL-MI; PUFA; Mortality; CAD; HVPG; T2D; TACE; HCC; EMR; HOMA-IR; FLINT; APRI; HCV; CRN; N/A; NAFLD; NR; NS; GBD; UoC; INR; HDL; LDL; MACE; GA; CKD; HbA1c; eGFR; OR; EOT; NAC; HCUP; NIS; CLD; AHC
• ISSN: 2772-5723; 2772-5723
• DOI: 10.1016/j.gastha.2022.06.016

Nonalcoholic steatohepatitis (NASH) is associated with increased mortality and risk of complications but is often asymptomatic and under-recognized. A systematic review of NASH epidemiology was conducted to provide information on the burden of NASH and highlight important evidence gaps for future research.
Medline, EMBASE, and Cochrane Library databases were searched for English-language publications published from 2010 to January 2022 that reported on natural history, risk factors, comorbidities, and complications of a NASH population or subpopulation.
Overall, 173 publications were included. NASH was shown to have a variable disease course and high prevalence of comorbid disease. Although many patients progressed to cirrhosis and end-stage liver disease, disease regression or resolution was reported in up to half of patients in some studies. Reported risk factors for disease progression or resolution included levels of (or changes in) serum fibrosis markers, liver enzymes, and platelets. The presence of NASH increased the risk of liver cirrhosis and other serious diseases such as hepatocellular carcinoma, colorectal cancer, chronic kidney disease, and cardiovascular disease. In 2017, NASH was responsible for ∼118,000 cirrhosis deaths globally, and an increasing proportion of patients are receiving liver transplantation for NASH in Europe and the United States. Consolidation of data was hampered by heterogeneity across the studies in terms of patient populations, follow-up time, and outcomes measured.
NASH is associated with significant morbidity and mortality, an increased risk of comorbidities, and imposes an increasing burden among liver transplantation recipients. Longer studies with harmonized study criteria are required to better understand the impact of NASH on patient outcomes.